Fingerprint
Dive into the research topics where Khandan Keyomarsi is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction
Luo, L., Wang, Y., Bui, T., Jiang, X., Chen, M. K., Rao, X., Mohammadhosseinpour, S., Li, M., Kim, S., Kim, R. Y., Kamaliasl, S., Ulizio, C. W., Tsavachidis, S., Navarro-Yepes, J., Kettner, N. M., Wingate, H., Meric-Bernstam, F., Hunt, K. K., Wang, J. & Faia, K. & 1 others, , Dec 2026, In: Nature communications. 17, 1, 619.Research output: Contribution to journal › Article › peer-review
Open Access2 Link opens in a new tab Scopus citations -
CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen
House, N. C., Chen, M. M., Khazaei, S., Brown, V., Ramsden, P., Peng, D. H., Moore, S., Yuan, L., Wu, R., Wang, F., Luo, L., Feng, N., Bristow, C. A., Yap, T. A., Keyomarsi, K., Marszalek, J. R., Ribich, S., Rinne, M. L., Muthuswamy, L. B. & Faia, K. L., Dec 2025, In: npj Breast Cancer. 11, 1, 135.Research output: Contribution to journal › Article › peer-review
Open Access4 Link opens in a new tab Scopus citations -
Cell cycle dysregulation in cancer
Glaviano, A., Singh, S. K., Lee, E. H. C., Okina, E., Lam, H. Y., Carbone, D., Reddy, E. P., O'Connor, M. J., Koff, A., Singh, G., Stebbing, J., Sethi, G., Crasta, K. C., Diana, P., Keyomarsi, K., Yaffe, M. B., Wander, S. A., Bardia, A. & Kumar, A. P., Mar 2025, In: Pharmacological Reviews. 77, 2, 100030.Research output: Contribution to journal › Review article › peer-review
47 Link opens in a new tab Scopus citations -
Corrigendum to “Cell cycle dysregulation in cancer” [Pharmacological Reviews 77 (2025) 100030] (Pharmacological Reviews (2025) 77(2), (S0031699724126300), (10.1016/j.pharmr.2024.100030))
Glaviano, A., Singh, S. K., Clarissa Lee, E. H., Okina, E., Lam, H. Y., Carbone, D., Reddy, E. P., O'Connor, M. J., Koff, A., Singh, G., Stebbing, J., Sethi, G., Crasta, K. C., Diana, P., Keyomarsi, K., Yaffe, M. B., Wander, S. A., Bardia, A. & Kumar, A. P., May 2025, In: Pharmacological Reviews. 77, 3, 100048.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models
Chen, M. K., Yamaguchi, H., Gao, Y., Xia, W., Chang, J. T., Hsiao, Y. C., Shegute, T. W., Lin, Z. S., Wu, C. S., Wang, Y. H., Litton, J. K., Ding, Q., Wei, Y., Chu, Y. Y., Meric-Bernstam, F., Piwnica-Worms, H., Arun, B., Ahnert, J. R., Liu, J. & Yao, J. & 12 others, , Jul 15 2025, In: Journal of Clinical Investigation. 135, 14, e173757.Research output: Contribution to journal › Article › peer-review
Open Access7 Link opens in a new tab Scopus citations